Alligator Bioscience AB

Alligator Bioscience AB

Forskning inom bioteknik

Om oss

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator´s technology platform comprises the proprietary technologies ALLIGATOR-GOLD® and FIND®. ALLIGATOR-GOLD® is a human antibody library containing more than 60 billion unique antibody fragments. FIND® (Fragment Induced Diversity) is a molecular evolution technology for optimization of antibodies and other proteins. Immunotherapy of cancer: The immune system protects the body from attacks by pathogenic microorganisms (e.g. viruses and bacteria) and by cancer cells. Cancer cells usually evade the immune system, for example by producing immunosuppressive substances. Thus, although tumors often contain a large number of immune cells that should be able to attack the cancer cells, they are unable to do so due to the immunosuppression caused by the tumor. With immunotherapy, the ability of the immune system to fight cancer cells is improved in an effective manner, and the defense mechanisms used by the tumor are blocked or weakened. In addition, immune cells capable of destroying the cancer cells will survive in the body and thus protect it from metastases that may arise after treatment has ended. This "vaccination effect" is unique for immunotherapy.

Bransch
Forskning inom bioteknik
Företagsstorlek
11–50 anställda
Huvudkontor
Lund
Typ
Publikt aktiebolag
Grundat
2001
Specialistområden
Immunotherapy of cancer, Immuno-oncology, CD40 och Combination therapy

Adresser

Anställda på Alligator Bioscience AB

Uppdateringar

Liknande sidor

Finansiering

Alligator Bioscience AB 1 runda totalt

Senaste finansieringsrunda

Okänd serie

7 426 017,00 US$

Se mer info på crunchbase